<DOC>
	<DOCNO>NCT01173029</DOCNO>
	<brief_summary>Renin-angiotensin-aldosterone system ( RAAS ) polymorphisms influence 24h arterial pressure fluctuation . Resistant systemic arterial hypertension ( RSAH ) increase risk end organ damage unfavourable prognosis , whereas pseudo-RSAH usually respond favourably drug therapy . To prospectively investigate , subject RSAH tropical South American city : 1 ) Adverse cardiovascular event define fatal non-fatal stroke acute myocardial infarction ( AMI ) ; 2 ) association RAAS polymorphisms adverse cardiovascular event population . Study population : 212 hypertensive recruit primary care assistance ( time since first diagnosis hypertension : 16.5±8.1 year ) without appropriate pressure control , 2001 2006 , correspond 0.48 % hypertensive care ( 18 new cases/year ) , 57±10 year old , 66 % female . Under drug treatment schedule : three drug include diuretic . Ninety two randomly select hypertensive basis renin-angiotensin-aldosterone system genetic profile determine . Genetic assessment carry use polymerase chain reaction assay amplification technique . The following single nucleotide polymorphism analyze : renin ( G1051A ) , angiotensinogen ( M235T ) , angiotensin convert enzyme-ACE ( I/D ) , angiotensin II type 1 receptor ( A1166C ) , aldosterone synthase ( C344T ) mineralocorticoid receptor ( G3514C ) .</brief_summary>
	<brief_title>Renin-angiotensin-aldosterone System Polymorphisms Resistant Hypertension Adverse Cardiovascular Events</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Subjects uncontrolled systemic arterial hypertension despite use three antihypertensive drug , include one diuretic Secondary cause systemic arterial hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Systemic arterial hypertension</keyword>
	<keyword>Hypertension Resistant Conventional Therapy</keyword>
	<keyword>Genetic polymorphism</keyword>
	<keyword>Renin-angiotensin-aldosterone system genetic polymorphism</keyword>
	<keyword>Risk marker</keyword>
	<keyword>Adverse event</keyword>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Stroke</keyword>
</DOC>